Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice

Neuroscience

Volumn 288, Issue , 2015, Pages 112-119

  Zhu, W ^a   Dotson, A L ^a,b   Libal, N L ^a   Lapato, A S ^a,b   Bodhankar, S ^a,b   Offner, H ^a,b   Alkayed, N J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

HLA DR2 transgenic mice; Immunotherapy; Ischemic stroke; Recombinant T cell receptor ligand

Indexed keywords

HLA DR2 ANTIGEN; RECOMBINANT RECEPTOR; RECOMBINANT T LYMPHOCYTE RECEPTOR LIGAND 1000; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; HLA DRB1 ANTIGEN; HYBRID PROTEIN; NEUROPROTECTIVE AGENT; RTL1000 PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CD11B+ CD45HI CELL; CD3+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOLOGICAL PROCEDURES; INFLAMMATION; MALE; MICROGLIA; MIDDLE AGED; MIDDLE CEREBRAL ARTERY OCCLUSION; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; SPLEEN; ANIMAL; CEREBRAL ARTERY DISEASE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; STROKE; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; BRAIN; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; HLA-DRB1 CHAINS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE, TRANSGENIC; MICROGLIA; MONOCYTES; NEUROIMMUNOMODULATION; NEUROPROTECTIVE AGENTS; NEUTROPHILS; RANDOM ALLOCATION; RECOMBINANT FUSION PROTEINS; SPLEEN; STROKE; T-LYMPHOCYTES;

EID: 84921026009     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.12.037     Document Type: Article

References (30)

1. Burrows G.G., Chang J.W., Bachinger H.P., Bourdette D.N., Offner H., Vandenbark A.A. Design, engineering and production of functional single-chain T cell receptor ligands. Protein Eng 1999, 12:771-778.
2. Burrows G.G., Adlard K.L., Bebo B.F., Chang J.W., Tenditnyy K., Vandenbark A.A., Offner H. Regulation of encephalitogenic T cells with recombinant TCR ligands. J Immunol 2000, 164:6366-6371.
3. Burrows G.G., Chou Y.K., Wang C., Chang J.W., Finn T.P., Culbertson N.E., Kim J., Bourdette D.N., Lewinsohn D.A., Lewinsohn D.M., Ikeda M., Yoshioka T., Allen C.N., Offner H., Vandenbark A.A. Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells. J Immunol 2001, 167:4386-4395.
4. del Zoppo G.J., Becker K.J., Hallenbeck J.M. Inflammation after stroke: is it harmful?. Arch Neurol 2001, 58:669-672.
5. Dirnagl U., Klehmet J., Braun J.S., Harms H., Meisel C., Ziemssen T., Prass K., Meisel A. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke 2007, 38:770-773.
6. Dziennis S., Mader S., Akiyoshi K., Ren X., Ayala P., Burrows G.G., Vandenbark A.A., Herson P.S., Hurn P.D., Offner H.A. Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice. Metab Brain Dis 2011, 26:123-133.
7. Emsley H.C., Smith C.J., Gavin C.M., Georgiou R.F., Vail A., Barberan E.M., Hallenbeck J.M., del Zoppo G.J., Rothwell N.J., Tyrrell P.J., Hopkins S.J. An early and sustained peripheral inflammatory response in acute ischemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2001, 139:93-101.
8. Feuerstein G.Z., Zaleska M.M., Krams M., Wang X., Day M., Rutkowski J.L., Finklestein S.P., Pangalos M.N., Poole M., Stiles G.L., Ruffolo R.R., Walsh F.L. Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab 2008, 28:217-219.
9. Fisher M., Feuerstein G., Howells D.W., Hurn P.D., Kent T.A., Savitz S.I., Lo E.H. Update of stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250. STAIR Group.
10. Frenkel D., Huang Z., Maron R., Koldzic D.N., Hancock W.W., Moskowitz M.A., Weiner H.L. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J Immunol 2003, 171:6549-6555.
11. Gee J.M., Kalil A., Shea C., Becker K.J. Lymphocytes: potential mediators of postischemic injury and neuroprotection. Stroke 2007, 38(2 Suppl):783-788.
12. Gelderblom M., Leypoldt F., Steinbach K., Behrens D., Choe C.U., Siler D.A., Arumugam T.V., Orthey E., Gerloff C., Tolosa E., Magnus T. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009, 40:1849-1857.
13. Gonzalez-Gay M.A., Zanelli E., Khare S.D., Krco C.J., Zhou P., Inoko H., Griffiths M.M., Luthra H.S., David C.S. Human leukocyte antigen-DRB1*1502 (DR2-TGDW12) transgene reduces incidence and severity of arthritis in mice. Hum Immunol 1996, 50:54-60.
14. Huan J.Y., Meza-Romero R., Mooney J.L., Chou Y.K., Edwards D.M., Rich C., Link J.M., Vandenbark A.A., Bourdette D.N., Bachinger H.P., Burrows G.G. Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. J Chem Technol Biotechnol 2005, 80:2-12.
15. Hurn P.D., Subramanian S., Parker S.M., Afentoulis M.E., Kaler L.J., Vandenbark A.A., Offner H. T- and B-cell deficient mice with experimental stroke has reduced lesion size and inflammation. J Cereb Blood Flow Metab 2007, 27:1798-1805.
16. Jin R., Yang G., Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 2010, 87:779-789.
17. Muir K.W., Tyrrell P., Sattar N., Warburton E. Inflammation and ischemic stroke. Curr Opin Neurol 2007, 20:334-342.
18. Nilupul Perera M., Ma H.K., Arakawa S., Howells D.W., Markus R., Rowe C.C., Donnan G.A. Inflammation following stroke. J Clin Neurosci 2006, 13:1-8.
19. Pan J., Palmateer J., Schallert T., Hart M., Pandya A., Vandenbark A.A., Offner H., Hurn P.D. Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke. Transl Stroke Res 2014, 5:577-585.
20. Schmid I., Krall W.J., Uittenbogaart C.H., Braun J., Giorgi J.V. Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry 1992, 13:204-208.
21. Sinha S., Subramanian S., Proctor T.M., Kaler L.J., Grafe M., Dahan R., Huan J., Vandenbark A.A., Burrows G.G., Offner H. A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. J Neurosci 2007, 27:12531-12539.
22. Stroke therapy academic industry roundtable Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999, 30:2752-2758.
23. Subramanian S., Zhang B., Kosaka Y., Burrows G.G., Grafe M.R., Vandenbark A.A., Hurn P.D., Offner H. Recombinant T cell receptor ligand treats experimental stroke. Stroke 2009, 40:2539-2545.
24. Vandenbark A.A., Rich C., Mooney J., Zamora A., Wang C., Huan J., Fugger L., Offner H., Jones R., Burrows G.G. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J Immunol 2003, 171:127-133.
25. Wang C., Mooney J.L., Meza-Romero R., Chou Y.K., Huan J., Vandenbark A.A., Offner H., Burrows G.G. Recombinant TCR ligand induces early TCT signaling and a unique pattern of downstream activation. J Immunol 2003, 171:1934-1940.
26. Yilmaz G., Arumugam T.V., Stokes K.Y., Granger D.N. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006, 113:2105-2112.
27. Zhang W., Davis C.M., Edin M.L., Lee C.R., Zeldin D.C., Alkayed N.J. Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury. PLoS One 2013, 8:e61244.
28. Zhu W., Wang L., Zhang L., Palmateer J.M., Libal N.L., Hurn P.D., Herson P.S., Murphy S.J. Isoflurane preconditioning neuroprotection in experimental focal stroke is androgen-dependent in male mice. Neuroscience 2010, 169:758-769.
29. Zhu W., Casper A., Libal N.L., Murphy S.J., Bodhandar S., Offner H., Alkayed N.J. Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke. Transl Stroke Res 2014, [Epub ahead of print].
30. Zhu W., Libal N.L., Casper A., Bodhankar S., Offner H., Alkayed N.J. Recombinant T-cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke. Transl Stroke Res 2014, 5:612-617. 10.1007/s12975-014-0348-8.